急性髓系白血病资源利用回顾性分析

数据集获取（Figshare）

• 源站标题：Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
• DOI：10.6084/m9.figshare.4315841.v1
• 发布日期：2016-12-14
• 文件数：2 个
• 文件总体积：92.36 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Acute_myeloid_leukemia_a_retrospective_claims_analysis_of_resource_utilization_and_expenditures_for_newly_diagnosed_patients_from_first-line_induction_to_remission_and_relapse/4315841

命令行下载

curl -L -o "icmo_a_1267615_sm9833.docx" "https://ndownloader.figshare.com/files/7039322"
curl -L -o "icmo_a_1267615_sm2310.pdf" "https://ndownloader.figshare.com/files/7039325"

文件清单

• icmo_a_1267615_sm9833.docx（31.20 KB）
• icmo_a_1267615_sm2310.pdf（61.16 KB）

文件总体积 92.36 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective: The objective of this study was to estimate resource utilization and expenditures for patients with acute myeloid leukemia (AML) in a real-world claims database.
Research design and methods: AML patients were identified in MarketScan claims databases between 1 January 2009 and 31 January 2015. Patients had a minimum of two AML diagnosis codes, hospitalization within 14 days after initial diagnosis, and ≥6 months of enrollment before initial diagnosis. Patients were monitored from first-line induction to a record of remission. A subset had a record of a second treatment period, defined as time from relapse to remission. Patient demographics, AML risk factors, and comorbidities were recorded. Descriptive analysis of utilization and expenditures (in 2014 $US) were reported for each cohort.
Results: The inclusion criteria were met in 1597 patients (mean age, 58.4 years; 51.0% male). Ninety percent of patients had ≥1 risk factor for AML. Mean (SD) healthcare expenditures for patients from first-line induction to remission (n = 681) were $208,857 ($152,090). Of the 157 who had a record of relapse, 70 had a record of a second remission. Expenditures for these patients (n = 70) from relapse to remission were $142,569 ($208,307); 60% were admitted to a hospital for a mean of 18.5 hospital days, and 20% had ≥1 emergency room visit.
Conclusions: Although this claims-based analysis is limited by a lack of generalizability to noninsured populations and potential underreporting of certain events and diagnoses, we found that treating AML patients poses a significant healthcare burden, during both first-line induction and relapse. With people living longer, the number of cases of AML is expected to increase in the future.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.4315841.v1（source: https://tandf.figshare.com/articles/dataset/Acute_myeloid_leukemia_a_retrospective_claims_analysis_of_resource_utilization_and_expenditures_for_newly_diagnosed_patients_from_first-line_induction_to_remission_and_relapse/4315841）。